drugset
drugset / Trial / NCT04620681

CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

NCT04620681 ↗

Phase 1/2 Completed 19 enrolled H. Lee Moffitt Cancer Center and Research Institute
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute myeloid leukemia (AML). Funding source - FDA OOPD.

Timeline

Start
2021-01-14
Primary completion
2024-07-20
Completion
2024-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes Cell therapy 1e+06 cells/kg Other
Subject CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes Cell therapy 1e+07 cells/kg Other
Subject CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes Cell therapy 5e+07 cells/kg Other

Indications

acute myeloid leukemia myelodysplastic syndrome